Follow up duration of phase III Multiple Myeloma Clinical Trials: A systematic review-Reference-Cited by-同舟云学术

Follow up duration of phase III Multiple Myeloma Clinical Trials: A systematic review

Published:2023-06-29 Issue:3 Volume:4 Page:719-722
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Ali Mohammad O.¹,Abdullah Hafez M.¹,Obeidat Khaldun²,Chakraborty Rajshekhar³,Al Hadidi Samer⁴^ORCID

Affiliation:

1. Department of Internal Medicine Sanford School of Medicine University of South Dakota Sioux Falls South Dakota USA

2. Department of Internal Medicine John H Stroger Jr Hospital of Cook County Chicago Illinois USA

3. Multiple Myeloma and Amyloidosis Program Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center New York New York USA

4. Myeloma Center, Winthrop P. Rockefeller Cancer Institute University of Arkansas for Medical Sciences Little Rock Arkansas USA

Abstract

AbstractLong‐term follow‐up of multiple myeloma (MM) clinical trials are needed to assess long‐term outcomes. We aimed to investigate the length of follow‐up of all phase III MM clinical trials. Median follow‐up duration of clinical trials of newly diagnosed MM was longer when compared to relapsed/refractory MM clinical trials (42.7 vs. 20.5 months, respectively). The follow‐up duration of phase III clinical trials in MM is relatively short when compared to the improved outcomes in the current era. Efforts should be made to facilitate long‐term clinical trials follow‐up and/or publication of results of updated results.

Publisher

Wiley

Subject

General Earth and Planetary Sciences

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.680

Reference12 articles.

1. Surveillance Epidemiology and End Results (SEER) Program(www.seer.cancer.gov) SEER*Stat Database: Mortality ‐ All COD Aggregated With State Total U.S. (1969‐2019) Katrina/Rita Population Adjustment National Cancer Institute DCCPS Surveillance Research Program released April 2021. Underlying mortality data provided by NCHS (www.cdc.gov)

2. Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma

3. The R Project for Statistical Computing.R: a language and environment for statistical computing. 2013. Accessed November 18 2022.http://www.r‐project.org/

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma;American Journal of Hematology;2024-08-07

2. Three Years Maintenance with VRD in Multiple Myeloma: Results of Total Therapy IIIB with a 15-Year Follow Up;Blood Advances;2023-12-05